師資
個人簡介：
田君，博士，南方科技大學醫學院助理教授（獨立PI）、副研究員、博士生導師。2018年博士畢業于加拿大麥吉爾大學，2019-2023年在美國哈佛醫學院麻省總醫院從事博士后研究。2023年8月加入南方科技大學醫學院。主要研究領域為癌癥的靶向和免疫治療，在尋找藥物耐藥性的機制，研究和開發新的聯合治療策略，腫瘤類器官模型的建立和藥物測試等方面取得了一系列成果。近年來共發表SCI論文十余篇，其中第一作者或通訊作者論文發表于Nature Medicine、Molecular Cancer (In press)、Briefings in Bioinformatics、British Journal of Cancer等國際高水平期刊雜志。于2022年獲得美國國立衛生院/哈佛癌癥中心研究基金。回國后獲得廣東省珠江人才青年學者稱號以及國家自然科學基金委和深圳市科創委等多項基金資助。
教育背景：
2009-2013 南開大學，學士
2013-2018 加拿大麥吉爾大學，博士
工作經歷：
2023.08-至今 南方科技大學醫學院，助理教授
2019-2023 美國哈佛醫學院麻省總醫院，博士后
2018-2019 加拿大麥吉爾大學健康中心，博士后
獲獎情況及榮譽：
2018 加拿大麥吉爾大學優秀博士畢業生獎
2017 加拿大麥吉爾大學醫學院優秀生產力獎
研究領域：
基礎研究：（1）研究致癌信號通路對腫瘤免疫微環境的影響；（2）研究腫瘤的靶向藥和免疫治療的協同作用；（3）腫瘤靶向藥物的耐藥機制。以消化道腫瘤，胰腺癌等為主要研究癌種。
臨床轉化應用研究：通過發現新的腫瘤靶向藥和免疫治療的應答/耐藥機制，設計針對不同突變型（如KRAS突變）患者的藥物聯合治療方案；尋找患者對藥物聯合治療反應/耐藥的生物標記物。
人源腫瘤類器官模型的建立：腫瘤藥物的療效評估、機制研究和生物標志物的發現。
學術任職：
雜志Frontiers in Genetics審稿人
美國癌癥研究協會會員
發表論文：
1. Xia Wang, Jing Wu, Aotian Xiao, Jie Wang*, Jun Tian*; Evolution of Direct RAS Inhibitors: From Undruggable Target to Clinical Breakthroughs, Molecular Cancer, 2025 (In press)
2. Liuyang Zhao , Landu Jiang , Yufeng Xie , JianHao Huang ,Haoran Xie, Jun Tian*, Dian Zhang*; scDTL: enhancing single-cell RNA-seq imputation through deep transfer learning with bulk cell information. Briefings In Bioinformatics, 2024, 25(6)
3. Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh, Oladapo O Yeku, Niya Xiong, Colin D Weekes, Jennifer Veneris, Leanne G Ahronian, Gianluca Mauri, Jun Tian, Bryanna L Norden, Alexa G Michel, Emily E Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J Fetter, Joan S Brugge, Helen Chen, Naoko Takebe, Richard T Penson, Dejan Juric, Keith T Flaherty, Ryan J Sullivan, Jeffrey W Clark, Rebecca S Heist, Ursula A Matulonis, Joyce F Liu*, Geoffrey I Shapiro*; Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clinical Cancer Research, 2024, 30(9), 1739-1749.
4. Jun Tian; Jonathan H. Chen; Sherry X. Chao; Karin Pelka; Marios Giannakis; Julian Hess; Kelly Burke; Vjola Jorgji; Princy Sindurakar; Jonathan Braverman; Arnav Mehta; Tomonori Oka; Mei Huang; David Lieb; Maxwell Spurrell; Jill N. Allen; Thomas A. Abrams; Jeffrey W. Clark; Andrea C. Enzinger; Peter C. Enzinger; Samuel J. Klempner; Nadine J. McCleary; Jeffrey A. Meyerhardt; David P. Ryan; Matthew B. Yurgelun; Katie Kanter; Emily E. Van Seventer; Islam Baiev; Gary Chi; Joy Jarnagin; William B. Bradford; Edmond Wong; Alexa G. Michel; Isobel J. Fetter; Giulia Siravegna; Angelo J. Gemma; Arlene Sharpe; Shadmehr Demehri; Rebecca Leary; Catarina D. Campbell; Omer Yilmaz; Gad A. Getz; Aparna R. Parikh; Nir Hacohen; Ryan B. Corcoran ; Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial, Nature Medicine, 2023, 29: 458-466
5. Yi Sun; Or-yam Revach; Seth Anderson; Emily A. Kessler; Clara H. Wolfe; Anne Jenney; Caitlin E. Mills; Emily J. Robitschek; Thomas G. R. Davis; Sarah Kim; Amina Fu; Xiang Ma; Jia Gwee; Payal Tiwari; Peter P. Du; Princy Sindurakar; Jun Tian; Arnav Mehta; Alexis M. Schneider; Keren Yizhak; Moshe Sade-Feldman; Thomas LaSalle; Tatyana Sharova; Hongyan Xie; Shuming Liu; William A. Michaud; Rodrigo Saad-Beretta; Kathleen B. Yates; Arvin Iracheta-Vellve; Johan K. E. Spetz; Xingping Qin; Kristopher A. Sarosiek; Gao Zhang; Jong Wook Kim; Mack Y. Su; Angelina M. Cicerchia; Martin Q. Rasmussen; Samuel J. Klempner; Dejan Juric; Sara I. Pai; David M. Miller; Anita Giobbie-Hurder; Jonathan H. Chen; Karin Pelka; Dennie T. Frederick; Susanna Stinson; Elena Ivanova; Amir R. Aref; Cloud P. Paweletz; David A. Barbie; Debattama R. Sen; David E. Fisher; Ryan B. Corcoran; Nir Hacohen; Peter K. Sorger; Keith T. Flaherty; Genevieve M. Boland; Robert T. Manguso; Russell W. Jenkins ; Targeting TBK1 to overcome resistance to cancer immunotherapy, Nature, 2023, 615(7950): 158-167
6. Tian, Jun; Wang, Vivian; Wang, Ni; Khadang, Baharak; Boudreault, Julien; Bakdounes, Khldoun; Ali, Suhad; Lebrun, Jean-Jacques ; Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition, BREAST CANCER RESEARCH, 2021, 23(1)
7. Shams, Anwar; Binothman, Najat; Boudreault, Julien; Wang, Ni; Shams, Fuad; Hamam, Dana; Tian, Jun; Moamer, Alaa; Dai, Meiou; Lebrun, Jean-Jacques; Ali, Suhad ; Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis, ONCOGENESIS, 2021, 10(1)
8. Jun Tian; Fatmah Al Raffa; Meiou Dai; Alaa Moamer; Baharak Khadang; Ibrahim Y.Hachim; Khldoun Bakdounes; Suhad Ali; Bertrand Jean-Claude; Jean-Jacques Lebrun ; Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells, British Journal of Cancer, 2018, 119(12): 1495-1507
9. Jun Tian; Amal A.Al-Odaini; Yun Wang; Juliana Korah; Meiou Dai; Lan Xiao; Suhad Ali; Jean-Jacques Lebrun ; KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer, Cellular Signalling, 2018, 42: 10
10. Jun Tian; Mahmood Y.Hachim; Ibrahim Y.Hachim; Meiou Dai; Chieh Lo; Fatmah Al Raffa; Suhad Ali; Jean Jacques Lebrun ; Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triplenegative breast cancer, Scientific Reports, 2017, 7: 40258
11. Hongru Zhang; Zheng Li; Li Wang; Gaofei Tian; Jun Tian; Zishan Yang; Guangchao Cao; Hong Zhou; Liqing Zhao; Zhenzhou Wu; Zhinan Yin ; Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function, Frontiers in Immunology, 2017, 8(129)
12. Laure Humbert; Mostafa Ghozlan; Lucie Canaff; Jun Tian; Jean-Jacques Lebrun ; The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma, BMC Cancer, 2015, 15(1): 200
13. Jimin Guo; Lucie Canaff; Charles Vincent Rajadurai; Nadège Fils-Aimé; Jun Tian; Meiou Dai; Juliana Korah; Manuel Villatoro; Morag Park; Suhad Ali; Jean-Jacques Lebrun ; Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes, Breast Cancer Research, 2014, 16(6): 476